Bortezomib

Introduction Overview

Generic Name

bortezomib

Brand Name

Velcade

Dosage Form

Single-dose vial lyophilized powder for reconstitution (3.5 mg)

Drug Class

Proteasome inhibitors

Pharmacokinetics

Absorption:
Bortezomib is administered via intravenous (IV) injection or subcutaneous (SC) injection, bypassing the gastrointestinal tract entirely and thus eliminating variability due to gastrointestinal absorption factors. Following IV administration, bortezomib shows rapid systemic distribution. SC administration results in a slower absorption phase but achieves comparable systemic exposure (area under the curve) to IV dosing. The bioavailability of subcutaneous bortezomib has been established to be approximately 70% to 80%, providing effective systemic levels with a more favorable safety and tolerability profile, including reduced peripheral neuropathy incidence.

Distribution:
Once in systemic circulation, bortezomib exhibits extensive distribution with a large volume of distribution, indicating wide tissue penetration. Studies suggest that bortezomib readily penetrates into various tissues, including bone marrow, which is the site of multiple myeloma. It is extensively bound to plasma proteins, which modulates free active drug concentration. Bortezomib does not significantly cross the blood-brain barrier; however, rare cases of central nervous system toxicity have been reported, likely due to secondary effects or disease-related factors.

Metabolism:
Bortezomib is primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP3A4, CYP2C19, and CYP1A2 isoforms. It undergoes oxidative deboronation, producing multiple metabolites; however, these metabolites are inactive, with no significant proteasome inhibitory activity. Individual variability in CYP enzymes and hepatic function can affect the metabolism and clearance of bortezomib, hence dosage adjustments or careful monitoring may be required in hepatic impairment. Drug interactions involving CYP3A4 inducers or inhibitors can alter bortezomib exposure.

Elimination:
Bortezomib has a complex elimination profile characterized by a terminal half-life ranging approximately from 40 to 190 hours depending on individual patient factors and dosing regimen. The drug is eliminated mainly through hepatic metabolism, with subsequent excretion of metabolites in urine and feces; less than 10% of unchanged bortezomib is excreted in urine. The prolonged terminal elimination phase contributes to the dosing intervals varying from once to twice weekly. Renal impairment is not expected to significantly affect bortezomib clearance since metabolism rather than renal excretion predominates, although close monitoring is advised in severe renal dysfunction. The pharmacokinetic profile supports intermittent dosing allowing recovery from toxicities while maintaining antitumor activity.

Dosage Forms

Available Dosage Forms:
- Single-dose vial containing 3.5 mg of bortezomib as a lyophilized powder for reconstitution.

Dosages for Adults and Adolescents:
- For previously untreated multiple myeloma: 1.3 mg/m2 administered as a 3-5 second bolus IV injection or subcutaneous injection in combination with oral melphalan and prednisone, given twice weekly for cycles 1 through 4 and once weekly for cycles 5 through 9. The typical regimen involves dosing on days 1, 4, 8, 11, 22, 25, 29, and 32 for the initial four cycles and days 1, 8, 22, and 29 in subsequent cycles.
- For relapsed multiple myeloma: 1.3 mg/m2 IV or SC twice weekly for two weeks (days 1, 4, 8, and 11) followed by a 10-day rest (days 12-21), with the option to continue therapy beyond eight cycles or switch to once-weekly dosing.
- For previously untreated mantle cell lymphoma: 1.3 mg/m2 IV bolus twice weekly combined with rituximab, cyclophosphamide, doxorubicin, and prednisone for two weeks followed by a 10-day rest (days 1, 4, 8, and 11; days 12-21 rest).
- For relapsed mantle cell lymphoma: Same dosing schedule as relapsed multiple myeloma.

Specific Patient Populations:
- Dosage adjustments are considered based on tolerability, underlying conditions, and response.
- Patients with hepatic impairment may require careful monitoring and possible dose modification due to altered metabolism.
- Use with caution in patients with pre-existing neuropathy, as bortezomib can exacerbate neuropathic symptoms.
- Pediatric dosing is not established; use is primarily in adult populations.
- No specific renal dosing adjustment is required but monitoring is advised.

Velcade must be reconstituted immediately prior to use and administered under the supervision of experienced healthcare professionals. The dosing intervals require at least 72 hours between consecutive doses to minimize toxicity and optimize therapeutic effects.

Mechanism Of Action

Velcade (bortezomib) functions primarily as a selective, reversible inhibitor of the 26S proteasome, a complex responsible for degrading ubiquitinated proteins within the cell. The 26S proteasome plays a vital role in maintaining cellular homeostasis by regulating the degradation of intracellular proteins involved in cell cycle progression, apoptosis, and stress responses. By inhibiting the proteasome, bortezomib disrupts these processes, leading to an accumulation of misfolded or regulatory proteins.

This accumulation triggers endoplasmic reticulum stress and activates apoptotic pathways, particularly in rapidly proliferating malignant cells like multiple myeloma and mantle cell lymphoma cells, which are highly dependent on proteasomal degradation for survival. The inhibition results in cell cycle arrest and apoptosis selectively in cancer cells due to their heightened proteasomal activity and protein synthesis demands.

Additionally, bortezomib modulates the tumor microenvironment by reducing the secretion of pro-inflammatory cytokines and altering adhesion molecule expression, thereby impairing tumor cell interactions with the bone marrow stroma. This contributes to its anti-cancer efficacy by disrupting survival signals.

Comparatively, bortezomib’s reversible inhibition differs from other proteasome inhibitors with irreversible action, affecting the duration of proteasome suppression. Clinical studies have demonstrated its efficacy in improving survival in multiple myeloma and mantle cell lymphoma. Research continues into combining bortezomib with other agents to enhance response rates and overcome resistance mechanisms, such as upregulation of compensatory proteolytic pathways.

Pharmacological Actions

Selective and reversible inhibition of the 26S proteasome catalytic activity.
Induction of apoptosis in malignant plasma cells and lymphoma cells by disrupting protein homeostasis.
Inhibition of NF-κB activation by preventing degradation of IκB, reducing proliferation and survival signaling.
Modulation of tumor microenvironment including suppression of cytokine secretion and cell adhesion interactions.
Disruption of cell cycle progression leading to G2-M phase arrest in cancer cells.
Enhancement of cancer cell sensitivity to other chemotherapeutic agents through combination regimens.
Reduction of angiogenesis within tumor sites by affecting endothelial cell function.
Altering immune response dynamics by affecting antigen presentation and immune cell activity.
Promotion of oxidative stress and mitochondrial dysfunction leading to apoptotic cell death.
Exertion of anti-lymphoproliferative effects in mantle cell lymphoma and multiple myeloma.

Therapeutic Or Clinical Uses

Treatment of multiple myeloma, including newly diagnosed and relapsed/refractory cases.
Management of mantle cell lymphoma in untreated and relapsed patients.
Use in combination regimens with melphalan and prednisone for multiple myeloma.
Combination therapy with rituximab, cyclophosphamide, doxorubicin, and prednisone in mantle cell lymphoma.
Treatment option for patients with relapsed multiple myeloma previously responsive to bortezomib.
Part of maintenance therapy protocols to prolong remission duration in multiple myeloma.
Utilized in patients ineligible for high-dose chemotherapy and stem cell transplantation.
Off-label or investigational use in other hematologic malignancies under clinical trials.
Reducing tumor burden and improving progression-free survival and overall survival metrics.
Adjunct to immunomodulatory drugs or monoclonal antibodies in combination therapy approaches.

Side Or Adverse Effects

Peripheral neuropathy presenting as numbness, tingling, burning pain, or muscle weakness.
Gastrointestinal symptoms including nausea, vomiting, diarrhea, and constipation.
Hematologic toxicity such as thrombocytopenia, neutropenia, and anemia leading to infection risk and bleeding.
Fatigue and malaise commonly reported during therapy.
Injection site reactions including pain, bruising, or swelling for subcutaneous administration.
Skin rash and pruritus associated with hypersensitivity.
Increased risk of infections, including viral reactivations such as herpes zoster.
Cardiac effects including heart failure symptoms and arrhythmias in susceptible patients.
Rare but serious neurological events including progressive multifocal leukoencephalopathy (PML).
Tumor lysis syndrome with rapid tumor breakdown causing metabolic disturbances.
Liver function abnormalities manifesting as elevated transaminases, jaundice, or hepatic failure.
Thrombotic microangiopathy with symptoms of bruising, bleeding, or decreased urine output.
Potential for severe hypersensitivity reactions including anaphylaxis.
Blurred vision and dizziness leading to impairment of coordination and balance.
Electrolyte imbalances such as hypokalemia or hypocalcemia associated with treatment.

Precautions

Patients should be monitored closely for new or worsening peripheral neuropathy; dose modifications may be necessary.
Caution in patients with pre-existing cardiovascular disease or congestive heart failure.
Close monitoring of blood counts is essential to detect and manage cytopenias early.
Avoid use in patients with hypersensitivity to bortezomib, mannitol, or boron.
Use with caution in patients with hepatic impairment due to altered metabolism.
Preventive antiviral therapy (e.g., acyclovir) is recommended to reduce risk of herpes zoster reactivation.
Maintain hydration and monitor renal function especially in patients with baseline kidney disease.
Educate patients about signs of infection and bleeding, and instruct them to seek immediate care.
Pregnancy prevention is critical; both male and female patients must use effective contraception during and after treatment.
Avoid concurrent use of potentially neurotoxic agents to reduce additive neurotoxicity risk.
Adjust dosing schedule to allow at least 72 hours between doses to minimize toxicity.
Be cautious in diabetic patients as neuropathy symptoms may worsen.
Regular ophthalmologic assessments may be warranted due to potential vision disturbances.
Monitor for signs of tumor lysis syndrome, especially in patients with high tumor burden.
Ensure patient adherence to reconstitution and administration guidelines to maintain drug stability and efficacy.

Warnings

May cause progressive multifocal leukoencephalopathy (PML), a rare but potentially fatal brain infection.
Risk of severe peripheral neuropathy, which can be dose-limiting and potentially irreversible.
Risk of severe hematologic toxicities including thrombocytopenia, neutropenia, and anemia leading to serious infections or bleeding.
Potential for tumor lysis syndrome in patients with high tumor burden; requires monitoring and prophylaxis.
May cause severe hypersensitivity reactions, including anaphylaxis.
Use with caution in patients with cardiovascular disease; reports of heart failure and cardiac ischemia have occurred.
Risk of thrombotic microangiopathy presenting with multi-organ involvement.
Avoid live vaccines during treatment due to immunosuppressive effects.
Pregnancy Category D: Teratogenic and embryotoxic effects demonstrated; contraindicated in pregnancy.
May impair ability to drive or operate machinery due to dizziness or blurred vision.
May cause secondary malignancies due to mutagenic potential, although data is limited.
Caution in patients with hepatic and renal impairment; metabolism and clearance may be affected.
Risk of gastrointestinal toxicity including severe diarrhea and vomiting requiring supportive care.
Reactivation of latent viruses including hepatitis B has been reported.
Treatment interruption or discontinuation may be necessary for severe toxicities.

Contraindication

Known hypersensitivity to bortezomib, mannitol, or boron-containing compounds.
Pregnancy, due to potential teratogenic effects affecting the fetus.
Patients with significant baseline peripheral neuropathy warranting avoidance or careful dose adjustment.
Severe hepatic impairment without adequate monitoring and possible dose modifications.
Use of live or live attenuated vaccines during treatment.
Severe uncontrolled infections or active serious infections at the time of planned therapy.
Known hypersensitivity to any component of the formulation including inactive ingredients.
Patients with bleeding disorders unless benefits outweigh risks and under careful supervision.
Concurrent participation in another investigational drug study without approval.
Any condition in which the potential risks outweigh the expected therapeutic benefits as judged by the healthcare provider.

Drug Interactions

CYP3A4 inhibitors (such as ketoconazole, erythromycin) may increase bortezomib plasma levels, enhancing toxicity risk.
CYP3A4 inducers (such as rifampin, phenytoin) can reduce bortezomib efficacy by increasing metabolism.
Co-administration with other neurotoxic agents (e.g., vincristine) may exacerbate peripheral neuropathy.
Drugs that affect blood clotting, like anticoagulants and antiplatelet agents, may increase bleeding risk during therapy.
Concurrent use with immunosuppressants can augment risk of severe infections.
Medications affecting the QT interval require cautious use due to potential additive cardiac toxicities.
Live vaccines should be avoided due to immunosuppression caused by bortezomib.
Herbal supplements such as St. John's wort may induce CYP enzymes altering drug levels.
Bortezomib can alter hepatic enzyme activity potentially affecting metabolism of concomitant drugs.
Potential interactions with dexamethasone: may modify metabolism or adverse effect profile.
Combination with agents causing myelosuppression requires enhanced hematologic monitoring.
Use with strong CYP2C19 inhibitors or inducers may modify bortezomib metabolism.
Concomitant use with drugs causing QT prolongation may elevate risk of arrhythmias.
Bortezomib may interfere with the pharmacodynamics of other targeted therapies, requiring careful dosing and monitoring.
Antiviral prophylaxis (e.g., acyclovir) is recommended to mitigate viral reactivation risk.

Preparations Of The Drug

Velcade is supplied as a lyophilized powder in single-dose vials containing 3.5 mg of bortezomib.
Comes with inactive ingredient mannitol, USP, ensuring stability in the lyophilized formulation.
Vials should be stored at controlled room temperature between 15ºC and 30ºC (59ºF to 86ºF), protected from light.
The lyophilized powder requires reconstitution with sterile water prior to administration.
Reconstituted product must be used within 8 hours and may be stored at 25ºC (77ºF) in the vial or syringe prior to use.
Intravenous or subcutaneous administration routes are both approved for delivering the reconstituted drug.
Single-dose vial format supports precise dosing tailored to patient body surface area (mg/m2).
The preparation does not contain antimicrobial preservatives; aseptic technique is essential during reconstitution.
Manufacturer: Takeda Pharmaceuticals America, Inc., Lexington, MA.
The drug is supplied with prescribing information outlining storage, handling, and administration instructions.
Reconstituted Velcade solution appears as a clear, colorless to slightly yellow solution without particulate matter.
Each vial is accompanied by a package insert detailing dosing schedules, side effects, and contraindications.
Proper disposal of unused product and materials contaminated with Velcade must adhere to hazardous drug guidelines.
Preparation should be performed by trained healthcare professionals to ensure safety and efficacy.
Patient medication guides are provided to inform about drug use, side effects, and precautions.